Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide widely investigated for its ability to modulate pro-inflammatory cytokine expression in pulmonary and epithelial tissue models. As a premier USA-based manufacturer, PX1 Research supplies high-purity, analytical-grade Bronchogen designed exclusively for in vitro assay systems and preclinical laboratory research.
Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide widely investigated for its ability to modulate pro-inflammatory cytokine expression in pulmonary and epithelial tissue models. As a premier USA-based manufacturer, PX1 Research supplies high-purity, analytical-grade Bronchogen designed exclusively for in vitro assay systems and preclinical laboratory research.
Bronchogen is a short synthetic peptide comprising four amino acid residues: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (sequence: Ala-Glu-Asp-Leu or AEDL). Originating from broader research into tissue-specific peptide bioregulators, Bronchogen belongs to a class of low-molecular-weight short chains designed to interact directly with nuclear DNA and histone proteins. In cellular models, these short peptide sequences cross nuclear membranes to modulate transcriptional activity, influencing protein synthesis without requiring membrane-bound receptor cascades.
In experimental models of pulmonary physiology, Bronchogen functions as a chromatin-modifying agent. By binding to specific regulatory regions of genomic DNA, the peptide alters chromatin accessibility, thereby normalizing cellular metabolism in bronchial epithelial cells. Researchers evaluating pulmonary pathology utilize Bronchogen peptide to study mechanisms of cellular repair, cellular aging, and structural integrity under conditions of oxidative stress and acute local inflammation.
Pro-inflammatory cytokines—including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), and Interleukin-8 (IL-8)—serve as primary signaling molecules driving tissue remodeling, leukocyte recruitment, and hyper-reactivity in respiratory models. Excess accumulation of these cytokines often leads to extracellular matrix breakdown and chronic tissue degradation in preclinical assays. Experimental studies demonstrate that administration of Bronchogen in cell culture models significantly attenuates the transcription of these hyper-inflammatory signaling cascades.
In vitro data indicate that Bronchogen suppresses nuclear factor kappa B (NF-κB) nuclear translocation, a master transcriptional regulator of inflammatory gene networks. By down-regulating NF-κB activation in bronchial cell lines, researchers observe a corresponding decline in downstream pro-inflammatory cytokine expression. This molecular suppression reduces cellular oxidative stress and limits the production of reactive oxygen species (ROS), offering scientists a targeted tool for exploring cytokine-driven pulmonary dysfunction in controlled laboratory environments.
The integrity of the respiratory epithelial barrier is crucial when evaluating pathological challenges. In rodent models of toxic exposure and acute respiratory distress, Bronchogen has been evaluated for its capacity to restore cellular barrier functions and maintain intercellular tight junction proteins (such as occludin and zonula occludens-1). Preclinical studies suggest that by controlling local pro-inflammatory cytokine levels, Bronchogen inhibits aberrant fibroblast proliferation and prevents excessive collagen deposition that leads to fibrotic tissue scarring.
Furthermore, in vitro assays involving ciliated bronchial epithelium show that exposure to short bioregulatory peptides maintains ciliary beat frequency and mucus clearance dynamics during challenged state simulations. Investigating these cellular pathways allows researchers to assess how targeted peptide sequences protect pulmonary microarchitecture from irreversible damage caused by sustained cytokine storms.
When designing preclinical protocols to evaluate cytokine modulation and tissue repair, researchers frequently compare Bronchogen against other specialized bioregulatory peptides. While Bronchogen displays pronounced specificity for bronchial epithelial tissue, related peptides operate through complementary pathways. For instance, researchers studying immune cell maturation and systemic cytokine response frequently evaluate Thymogen, a synthetic dipeptide (Glu-Trp) targeting T-cell differentiation and general immunomodulation.
Similarly, Chonluten (Glu-Asp-Gly) is another pulmonary-focused short peptide evaluated for its protective effects on lung parenchyma and bronchial tissue architecture under toxic conditions. In broader studies of cellular senescence and systemic protein synthesis, investigators often include Epitalon to assess comparative telomerase activation and antioxidant gene expression. Selecting the correct compound within the PX1 Research catalog allows laboratories to isolate specific tissue-level responses versus systemic immunomodulatory mechanisms.
Bronchogen is supplied as a lyophilized (freeze-dried) sterile powder to ensure maximum chemical stability during transport and storage. For in vitro experiment design, proper reconstitution technique is essential to maintain peptide integrity and prevent premature enzymatic or chemical degradation. Laboratories should reconstitute Bronchogen under sterile laminar flow hoods using high-purity laboratory solvents.
Standard reconstitution protocols utilize sterile, non-bacteriostatic 0.9% Sodium Chloride or standard Phosphate-Buffered Saline (PBS, pH 7.4) for immediate cellular assays. If extended working solutions are required for multi-day in vitro studies, sterile Bacteriostatic Water containing 0.9% benzyl alcohol may be utilized to prevent microbial contamination. Reconstituted solutions should be gently swirled rather than vortexed to prevent shear stress on the peptide backbone, and concentrated stock solutions should be aliquoted into single-use microcentrifuge tubes to eliminate freeze-thaw degradation cycles.
To guarantee valid, reproducible experimental outcomes, institutional research facilities must source peptides from professional manufacturers adhering to rigorous analytical standards. Substandard research compounds containing residual trifluoroacetic acid (TFA), unreacted precursor amino acids, or heavy metals introduce unwanted variables that distort cytokine assay measurements and cell culture viability.
A qualified peptide manufacturer must provide full batch-level verification using High-Performance Liquid Chromatography (HPLC) to confirm chemical purity and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight. Laboratories evaluating suppliers should review the technical literature on peptide purity testing via HPLC and MS to ensure their materials meet minimum purity thresholds—typically >98.0%—before initiating sensitive cellular work.
For research specifically focused on pro-inflammatory cytokines, endotoxin contamination represents a catastrophic confounding variable. Bacterial endotoxins (lipopolysaccharides, or LPS) are potent activators of Toll-like receptor 4 (TLR4), causing massive artifactual spikes in TNF-α, IL-6, and IL-1β expression in macrophage and epithelial cell models. If a research compound is contaminated with trace endotoxins, observed cytokine fluctuations cannot be accurately attributed to the peptide being evaluated.
PX1 Research enforces strict endotoxin screening protocols using Chromogenic Limulus Amebocyte Lysate (LAL) assays on every production lot. To protect cell culture integrity, research compounds must conform to ultra-low endotoxin thresholds (<0.01 EU/mg). For detailed methodology on how background endotoxins skew preclinical inflammation assays, researchers can consult our reference guide on endotoxin testing in laboratory peptides.
PX1 Research manufactures all research peptides within ISO 17025 accredited, GMP-compliant facilities located exclusively in the United States. Adherence to domestic manufacturing standards ensures strict environment control, eliminating contamination risks associated with unverified overseas production facilities. Every batch of Bronchogen undergoes rigorous analytical clearance prior to release.
Upon receipt, lyophilized Bronchogen should be stored in a freezer at -20°C for short-to-medium term storage, or at -80°C for long-term storage spanning up to two years. Reconstituted liquid aliquots must be kept at 2°C to 8°C and utilized within 7 to 14 days, or flash-frozen at -80°C for extended use. PX1 Research facilitates seamless cold-chain logistics, offering same-day dispatch Monday through Friday from centralized shipping hubs in California and Arizona to support uninterrupted academic and industrial research workflows.
Academic institutions, biotechnology firms, and contract research organizations (CROs) requiring large-scale synthesis or bulk lot consistency can access custom supply arrangements through PX1 Research. Maintaining lot-to-lot purity consistency across large experimental blocks is essential for multi-phase preclinical trials and drug discovery screening pipelines.
Through our dedicated wholesale procurement division, laboratories can order standardized bulk quantities with matching lot numbers, ensuring identical chromatographic profiles across long-term studies. Every bulk order includes complete analytical documentation, including raw mass spectra and high-resolution HPLC traces. Explore our complete research documentation hub to access full analytical methodologies and scientific literature whitepapers.
What is the specific primary chemical structure of Bronchogen?
Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu / AEDL), with a theoretical molecular weight of approximately 446.45 g/mol.
How does Bronchogen interact with pro-inflammatory cytokines in cellular models?
In vitro studies indicate that Bronchogen modulates chromatin structure in epithelial cells, leading to down-regulated nuclear factor kappa B (NF-κB) transcription. This results in reduced gene expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
Why is endotoxin testing critical when ordering Bronchogen for cytokine research?
Bacterial endotoxins (LPS) trigger strong inflammatory responses in cell cultures via TLR4 pathways, causing artificial increases in pro-inflammatory cytokines. PX1 Research tests every lot to ensure endotoxin levels remain below 0.01 EU/mg, eliminating background assay interference.
What solvents are recommended for reconstituting Bronchogen for in vitro assays?
For immediate cellular applications, sterile 0.9% Sodium Chloride or Phosphate-Buffered Saline (PBS, pH 7.4) is recommended. If multi-day sterile handling is required, sterile Bacteriostatic Water may be used.
What analytical methods verify the purity of PX1 Research Bronchogen?
Every lot of Bronchogen undergoes High-Performance Liquid Chromatography (HPLC) to confirm peptide purity (>98.0%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular identity and mass.
How should lyophilized Bronchogen be stored upon delivery?
Lyophilized powder should be stored at -20°C for short-term preservation or -80°C for long-term stability. Avoid repeated exposure to ambient temperature and humidity before reconstitution.
Is Bronchogen approved for therapeutic or clinical human use?
No. Bronchogen supplied by PX1 Research is strictly designated as a research-grade compound intended exclusively for in vitro laboratory experimentation and preclinical scientific evaluation. It is not for human or veterinary use.
Can institutional laboratories procure bulk lots of Bronchogen with matching COAs?
Yes, PX1 Research offers institutional wholesale accounts providing bulk quantities with lot-matched Certificate of Analysis (COA) documentation, HPLC chromatograms, and MS spectra.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.